Trial · NCT04411472
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day All-cause Mortality: Main Trial Population | 28 days | To demonstrate an effect of recAP on 28 day all cause mortality |
| Primary | 28-day All-cause Mortality: Moderate Chronic Kidney Disease Population | 28 days | To demonstrate an effect of recAP on 28 day all cause mortality |
| Primary | 28-day All-cause Mortality: COVID-19 Population | 28 days | To demonstrate an effect of recAP on 28 day all cause mortality |
| Secondary | Major Adverse Kidney Events 90: Main Trial Population | 90 Days | Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
| Secondary | Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population | 90 Days | Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
| Secondary | Major Adverse Kidney Events 90: COVID-19 Population | 90 Days | Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level. |
| Secondary | Major Adverse Kidney Events Through Day 90: Combined Population | 90 Days | Major Adverse Kidney Events through day 90 (MAKE90A) : * death until day 90 * greater than 25% drop in estimated glomerular filtration rate at Day 90 * on renal replacement therapy (RRT) at day 90 OR on RRT through Day 28 |
| Secondary | Days Alive and Free of Organ Support Through Day 28: Main Trial Population | 28 days | Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
| Secondary | Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population | 28 days | Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
| Secondary | Days Alive and Free of Organ Support Through Day 28: COVID-19 Population | 28 days | Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days) |
| Secondary | Days Alive and Out of the ICU Through Day 28: Main Trial Population | 28 days | Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
| Secondary | Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population | 28 days | Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
| Secondary | Days Alive and Out of the ICU Through Day 28: COVID-19 Population | 28 days | Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days). |
| Secondary | 90-day All Cause Mortality: Main Trial Population | 90 days | 90-Day all-cause mortality |
| Secondary | 90-day All Cause Mortality: Moderate Chronic Kidney Disease Population | 90 days | 90-Day all-cause mortality |
| Secondary | 90-day All Cause Mortality: COVID-19 Population | 90 days | 90-Day all-cause mortality |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04411472/registered